Proceedings of the Human Factors and Ergonomics Society Annual Meeting

The Society for Immunotherapy of Cancer Announces Late-Breaking Abstracts and Press Briefing Presented at 38th Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023

MILWAUKEE, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2023, more than 1,600, and has announced titles and authors for 30 accepted Late-breaking Abstracts (LBA). The abstracts will be presented at SITC's upcoming 38th Annual Meeting & Pre-Conference Programs taking place November 1–5, 2023, in San Diego, CA and virtually.

Key Points: 
  • The abstracts will be presented at SITC's upcoming 38th Annual Meeting & Pre-Conference Programs taking place November 1–5, 2023, in San Diego, CA and virtually.
  • SITC also invites you to attend the virtual press briefing of the society's 38th Annual Meeting (SITC 2023) beginning at 12:00 p.m. PDT on Wednesday, Nov. 1, 2023.
  • The abstracts will be presented at SITC's upcoming 38th Annual Meeting & Pre-Conference Programs taking place November 1–5, 2023, in San Diego, CA and virtually.
  • The abstracts selected for the press briefing represent an array of the top advances in cancer immunotherapy research.

H2O Innovation Announces Meeting Updates

Retrieved on: 
Friday, October 20, 2023

The Corporation intends to hold the Acquisition Meeting to consider the Arrangement on November 28, 2023.

Key Points: 
  • The Corporation intends to hold the Acquisition Meeting to consider the Arrangement on November 28, 2023.
  • The record date for the Acquisition Meeting will be October 24, 2023.
  • The Corporation announced today that it is postponing until December 22, 2023 its annual meeting of shareholders previously scheduled to be held on December 5, 2023 (the “Annual Meeting”).
  • The record date of October 26, 2023 for the Annual Meeting will remain the same, and meeting materials will be sent to shareholders of record in due course.

AOFAS Annual Meeting 2023 Highlights Orthopaedic Research and Innovation

Retrieved on: 
Thursday, September 28, 2023

ROSEMONT, Ill., Sept. 28, 2023 (GLOBE NEWSWIRE) -- More than 900 foot and ankle orthopaedic surgeons, advanced health practitioners, orthopaedic residents, and medical students attended the American Orthopaedic Foot & Ankle Society® (AOFAS) Annual Meeting on September 20-23, 2023.

Key Points: 
  • ROSEMONT, Ill., Sept. 28, 2023 (GLOBE NEWSWIRE) -- More than 900 foot and ankle orthopaedic surgeons, advanced health practitioners, orthopaedic residents, and medical students attended the American Orthopaedic Foot & Ankle Society® (AOFAS) Annual Meeting on September 20-23, 2023.
  • The meeting offered attendees 181 live presentations, 40 e-podium presentations, 300 poster presentations, and the opportunity to connect with 81 exhibiting companies.
  • Also at the Annual Meeting, AOFAS and the Arthritis Foundation (AF) announced the recipients of the first ever AF/AOFAS Ankle Arthritis Thank Tank Research Grants.
  • On the third day of the meeting, orthopaedic foot and ankle surgeon, Michael S. Aronow, MD, of Hartford, Connecticut, was installed as the 2023-24 president of the AOFAS Board of Directors.

Human Factors and Ergonomics Society's Human Factors Journal Receives Prestigious Recognition

Retrieved on: 
Tuesday, July 18, 2023

The Human Factors and Ergonomics Society ( HFES ), the world’s largest scientific association for human factors/ergonomics professionals, announced that the society’s journal, Human Factors, achieved its second-highest rating at 3.3 from the annual Journal Citation Reports (JCR) published by Clarivate.

Key Points: 
  • The Human Factors and Ergonomics Society ( HFES ), the world’s largest scientific association for human factors/ergonomics professionals, announced that the society’s journal, Human Factors, achieved its second-highest rating at 3.3 from the annual Journal Citation Reports (JCR) published by Clarivate.
  • First published in 1958, Human Factors is the flagship journal of the Human Factors and Ergonomics Society, covering a wide variety of topics, including automation, human systems integration, industrial engineering, robotics and more.
  • Editor-in-Chief of Human Factors, Rob Radwin, said, “It’s encouraging that the journal has maintained its strong level of impact this year, the new method of calculating impact factors notwithstanding.” The publication looks forward to cultivating further innovations, celebrating the accomplishments and implementing forward steps to improving human factors and ergonomics research and practice.
  • For more details and additional information on the latest findings in human factors/ergonomics research and practice, please visit Human Factors and Ergonomic Society’s Journals and Proceedings website page.

Pitney Bowes Announces Preliminary Results from its 2023 Annual Meeting of Shareholders

Retrieved on: 
Tuesday, May 9, 2023

The Company issued the following statement:

Key Points: 
  • The Company issued the following statement:
    “We welcome all new directors, including the nominees of Hestia Capital Partners, and look forward to working with them constructively on the future of the Company and on behalf of all shareholders.”
    The foregoing results announced today are subject to certification by the Independent Inspector of Election.
  • The Company anticipates that the final results of the Annual Meeting will be made available in a Current Report on Form 8-K filed with the Securities and Exchange Commission and on Pitney Bowes’ investor relations website in due course.

Toxicologist Dr. Barbara D. Beck Awarded Society of Toxicology (SOT) Metals Specialty Section Career Achievement Award

Retrieved on: 
Thursday, March 23, 2023

BOSTON, March 23, 2023 /PRNewswire/ -- Gradient is pleased to announce that Dr. Barbara D. Beck has been named the winner of the Career Achievement Award by the Society of Toxicology (SOT) Metals Specialty Section.

Key Points: 
  • Gradient scientist Dr. Barbara D. Beck was awarded the Society of Toxicology (SOT) Metals Specialty Section Career Achievement Award for her achievements in the field of metals toxicology at the SOT 62nd Annual Meeting.
  • BOSTON, March 23, 2023 /PRNewswire/ -- Gradient is pleased to announce that Dr. Barbara D. Beck has been named the winner of the Career Achievement Award by the Society of Toxicology (SOT) Metals Specialty Section.
  • The Career Achievement Award "recognizes a senior investigator whose outstanding research accomplishments have substantially advanced our understanding of metals toxicology.
  • Dr. Beck, a toxicologist and human health risk assessment scientist, is a long-time member of the Metals Specialty Section.

Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society

Retrieved on: 
Tuesday, March 7, 2023

WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts on VRDN-001 and VRDN-002—the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—will be presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), to be held March 11 to 16, 2023, in Orlando, Florida.

Key Points: 
  • - Additional poster presentations to cover trial design, early-stage clinical and mechanistic data on pipeline candidates in Company’s thyroid eye disease program -
    WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts on VRDN-001 and VRDN-002—the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—will be presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), to be held March 11 to 16, 2023, in Orlando, Florida.
  • An oral presentation with data from the ongoing Phase 1/2 trial of VRDN-001, a full antagonist antibody to the insulin-like growth factor 1 receptor (IGF-1R), is scheduled for the morning of Tuesday, March 14, with four posters from Viridian’s TED program to be presented that evening.
  • “We are pleased to present this encouraging data from our TED pipeline at this important annual gathering,” said Barrett Katz, M.D., M.B.A., Chief Medical Officer of Viridian.
  • “Taken together, the clinical and mechanistic data we are sharing at NANOS strengthen our confidence not only in VRDN-001 as we work to enroll patients in our active THRIVE Phase 3 trial, but also in our ability to develop follow-on assets with the potential for subcutaneous self-administration to decrease treatment burdens on patients and their families living with TED.”

Materion Corporation to Hold Annual Shareholder’s Meeting May 17

Retrieved on: 
Thursday, March 2, 2023

Materion Corporation (NYSE: MTRN) will hold its annual shareholder’s meeting (the Annual Meeting) at the Boston Marriott Newton hotel in Newton, Massachusetts on May 17, 2023, at 8:00 a.m. (EDT).

Key Points: 

Materion Corporation (NYSE: MTRN) will hold its annual shareholder’s meeting (the Annual Meeting) at the Boston Marriott Newton hotel in Newton, Massachusetts on May 17, 2023, at 8:00 a.m. (EDT).

Copland Road Capital Corporation Announces Results of Annual General and Special Meeting and Court Approval of Plan of Arrangement

Retrieved on: 
Friday, December 16, 2022

Vancouver, British Columbia--(Newsfile Corp. - December 16, 2022) - Copland Road Capital Corporation (CSE: CRCC) announced today that all resolutions were unanimously passed at its Annual General and Special Meeting of Shareholders (the "Annual Meeting").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - December 16, 2022) - Copland Road Capital Corporation (CSE: CRCC) announced today that all resolutions were unanimously passed at its Annual General and Special Meeting of Shareholders (the "Annual Meeting").
  • Subsequent to the Annual Meeting, the Company received a final order from the Supreme Court of British Columbia on December 13, 2022 approving the Arrangement as particularized in the Management Information Circular dated November 14, 2022 (the "Circular").
  • Copland Road Shareholders will receive Distributed Securities in proportion to their shareholdings in Copland Road and there will be no effective change in such Copland Road Shareholders' existing interests in Copland Road.
  • Following completion of the Plan of Arrangement, Copland Road will continue to carry on its primary business activities as an investment issuer.

Decentralized Trials & Research Alliance (DTRA) Shares Key Findings from Annual Meeting

Retrieved on: 
Thursday, November 10, 2022

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a non-profit organization dedicated to the global adoption of decentralized clinical trials and research within life sciences and healthcare, today announced several key initiative updates that will continue to progress throughout 2023. Specialized DTRA teams presented these initiatives during its 2nd Annual Meeting in Boston, MA, from November 6-9, 2022. The meeting was attended by select professionals from its global membership of leaders in decentralized clinical trials (DCTs) including regulators, pharmaceutical and biotechnology sponsors, contract research organizations (CROs) and other service providers, technology companies, research sites, and advocacy leaders.

Key Points: 
  • SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Decentralized Trials & Research Alliance (DTRA), a non-profit organization dedicated to the global adoption of decentralized clinical trials and research within life sciences and healthcare, today announced several key initiative updates that will continue to progress throughout 2023.
  • Specialized DTRA teams presented these initiatives during its 2nd Annual Meeting in Boston, MA, from November 6-9, 2022.
  • The Decentralized Trials & Research Alliance ( DTRA ), a non-profit organization, was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
  • It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.